Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Biocytogen Pharmaceuticals (Beijing) Co Receivables Turnover Related Terms
Biocytogen Pharmaceuticals (Beijing) Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co Receivables Turnover Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
FRA:I54 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Receivables Turnover of 3.03 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #387 out of 841 companies in the Biotechnology industry, placing it in the top 46%.
Is Biocytogen Pharmaceuticals (Beijing) Co's Receivables Turnover too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Receivables Turnover is 3.03. The Biotechnology industry median Receivables Turnover is 5.28. Biocytogen Pharmaceuticals (Beijing) Co's value of 3.03 is 42.6% below this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #387 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #387 out of 841 companies for Receivables Turnover. This puts Biocytogen Pharmaceuticals (Beijing) Co in the upper half of its industry. The industry median Receivables Turnover is 5.28. Biocytogen Pharmaceuticals (Beijing) Co's value of 3.03 is 42.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current Receivables Turnover of 3.03 is 42.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current Receivables Turnover is 3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.24, compared to a current price of €5.70 — trading 75.9% above its estimated fair value. The current Receivables Turnover is 3.03 and 42.6% below the Biotechnology industry median of 5.28. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Receivables Turnover is 3.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of €5.70 is trading 75.9% above its estimated GF Value™ of €3.24.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for FRA:I54:
Receivables Turnover: 3.03
GF Value™: €3.24 vs. price of €5.70 (75.9% above fair value)
Industry Position: 42.6% below the Biotechnology median (#387 of 841)
No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
79GF Score
Get the complete analysis for FRA:I54
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I54 has been successfully added to your 
